On December 9^th, 2021, CANbridge Pharmaceuticals Inc. (“CANbridge”) announced a Letter of Intent with Peking Union Medical College Hospital (“PUMCH”) on scientific research collaboration for rare diseases. In future, in joint efforts to push for the development of their medical, research, academic and industrial systems for rare diseases, both parties will utilize their respective strengths to collaborate on pharmaceutical innovation for rare diseases, integrated research and development in areas such as translational medicine and clinical trials, and further enhancement of research and development for innovative medicines for rare diseases.

James Xue, Ph.D., Founder, Chairman and CEO of CANbridge, said: “As the only national leading institution in the National Cooperation Network in Diagnosis and Treatment for Rare Diseases, PUMCH has accumulated a wealth of experience in diagnosis, treatment and clinical research for rare diseases. We are very happy that PUMCH and us have reached a Letter of  Intent. It is believed that under our joint efforts, both parties will be able to forge a path with Chinese characteristics for pharmaceutical R&D and innovation for rare diseases, so as to bring hopes for more rare disease patients and their families.”

About Peking Union Medical College Hospital:

Founded in 1921, Peking Union Medical College Hospital (“PUMCH”) is a modern class 3A hospital integrating medical treatment and teaching, as well as medical scientific research. As a national diagnosis and treatment guidance center for complex, severe and rare diseases appointed by the National Health Commission, the PUMCH was not only one of the earliest hospitals responsible for cadre health care and medical tasks for foreign guests, but also a national demonstration base for medical higher education and standard training for resident physicians, as well as a national core base for clinical research and technical innovation. The PUMCH is renowned both at home and abroad for its comprehensive disciplines, high technical capabilities, outstanding specialties, and integrated disciplinary strengths. The hospital claimed the top place twice in the performance appraisal for national tertiary public hospitals, and has been ranked top in the “Chinese Hospital Rankings” announced by the Hospital Management Institute, Fudan University for 12 consecutive years.

The PUMCH has always played a leading role in the diagnosis and treatment of rare diseases. In 2016, the hospital led a national key research and development plan named “Clinical Cohort Study of Complex, Severe and Rare Diseases” and established China’s registration system for national complex, severe and rare diseases, which has become one of the world’s largest rare disease information platforms. As a member of the Committee of Experts on the Diagnosis and Treatment of Rare Diseases and the Guarantee of Drug Supplies of the National Health Commission, the hospital led a team of top domestic experts in compiling China′s First List of Rare Diseases and played the role of editor-in-chief in publishing Compendium of China's First List of Rare Diseases, Guidelines for Diagnosis and Treatment of Rare Diseases (2019 version) (announced by the National Health Commission), and Textbook on Rare Diseases (a postgraduate textbook during the 13th Five-year Plan). In addition, the hospital conducted nationwide technical training in diagnosis and treatment for rare diseases. At present, the PUMCH is responsible for research tasks for the State Key Laboratory of Complex, Severe and Rare Diseases, National Center for Translational Medicine, national center for the National Cooperation Network in Diagnosis and Treatment for Rare Diseases, and national quality control center for rare diseases, laying a foundation for comprehensive clinical resources, technical advantages, and integrative diagnoses, treatment, research and innovation for rare diseases in China.

About CANbridge Pharmaceuticals Inc.

CANbridge Pharmaceuticals Inc. is a China-based global rare disease-focused biopharmaceutical company committed to the research, development, and commercialization of transformative therapies.

CANbridge has a comprehensive and differentiated pipeline of 13 drug assets with significant market potential, targeting some of the most prevalent rare diseases and rare oncology.

These include Hunter syndrome (MPS II) and other lysosomal storage disorders (LSDs), complement mediated disorders, hemophilia A, metabolic disorders, rare cholestatic liver diseases and neuromuscular diseases, as well as glioblastoma multiforme (GBM).

CANbridge strategically combines global collaborations and internal research to build and diversify its drug portfolio and invest in next-generation gene therapy technologies for rare disease treatments. CANbridge global partners include, but are not limited to, Apogenix, GC Pharma, Mirum, Wuxi Biologics, Privus, the University of Massachusetts Medical School (UMass), the University of Washington School of Medicine, and LogicBio and Scriptr.

For more on CANbridge Pharmaceuticals Inc., please go to: www.canbridgepharma.com.

Contact:

CANbridge Pharmaceuticals Inc.

ir@canbridgepharma.com

Media:

Deanne Eagle

Planet Communications

deanne@planetcommunications.nyc

917.837.5866